Bay Street News

Bay Street News, November 17th, 2024

Home / 2024 / November / 17
  0
NASDAQ Companies - November 17, 2024

Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024

SAN FRANCISCO, Nov. 17, 2024 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted […]

Read More
Load More
Navigation
  • Home
  • TSX News
  • TSX Venture News
  • NASDAQ Companies
  • NYSE Companies
  • Canadian Stock Exchange News
  • Pink Sheets News
  • OTCBB News
Latest News
  • Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024
  • Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis
  • Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024
  • Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024
  • DMG Blockchain Solutions Inc. Announces Filing of Prospectus Supplement in Respect of $15,004,300 Unit Offering

Tweets by baystnews

© 2020 BayStNews.com - All Rights Reserved
  • Home
  • TSX News
  • TSX Venture News
  • NASDAQ Companies
  • NYSE Companies
  • Canadian Stock Exchange News
  • Pink Sheets News
  • OTCBB News
Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt

Start typing and press Enter to search